Clorox Co Del Financials

CLX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE June

This page shows Clorox Co Del (CLX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 39/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

Clorox Co Del's revenue grew a modest 0.2% year-over-year to $7.1B. This slow but positive growth earns a score of 34/100.

Leverage

Clorox Co Del has elevated debt relative to equity (D/E of 7.74), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Clorox Co Del's current ratio of 0.84 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 11/100, which could limit financial flexibility.

Cash Flow

Clorox Co Del has a free cash flow margin of 10.7%, earning a moderate score of 52/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

100

Clorox Co Del earns a strong 252.3% return on equity (ROE), meaning it generates $252 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 85.4% the prior year.

Piotroski F-Score Strong

7/9

Clorox Co Del passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.21x

For every $1 of reported earnings, Clorox Co Del generates $1.21 in operating cash flow ($981.0M OCF vs $810.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$7.1B

YoY+0.2%

5Y CAGR+1.1%

10Y CAGR+2.3%

Clorox Co Del generated $7.1B in revenue in fiscal year 2025. This represents an increase of 0.2% from the prior year.

EBITDA

N/A

Net Income

$810.0M

YoY+189.3%

5Y CAGR-2.9%

10Y CAGR+3.4%

Clorox Co Del reported $810.0M in net income in fiscal year 2025. This represents an increase of 189.3% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

$761.0M

YoY+57.6%

5Y CAGR-10.0%

10Y CAGR+0.2%

Clorox Co Del generated $761.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 57.6% from the prior year.

Cash & Debt

$167.0M

YoY-17.3%

5Y CAGR-28.1%

10Y CAGR-7.9%

Clorox Co Del held $167.0M in cash against $2.5B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

122M

YoY-1.3%

5Y CAGR-0.6%

10Y CAGR-0.5%

Clorox Co Del had 122M shares outstanding in fiscal year 2025. This represents a decrease of 1.3% from the prior year.

Margins & Returns

Gross Margin

45.2%

YoY+2.3pp

5Y CAGR-0.3pp

10Y CAGR+1.6pp

Clorox Co Del's gross margin was 45.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the prior year.

Operating Margin

N/A

Net Margin

11.4%

YoY+7.5pp

5Y CAGR-2.6pp

10Y CAGR+1.1pp

Clorox Co Del's net profit margin was 11.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.5 percentage points from the prior year.

Return on Equity

252.3%

YoY+167.0pp

5Y CAGR+148.9pp

10Y CAGR-239.2pp

Clorox Co Del's ROE was 252.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 167.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$121.0M

YoY-4.0%

5Y CAGR-3.6%

10Y CAGR-1.2%

Clorox Co Del invested $121.0M in research and development in fiscal year 2025. This represents a decrease of 4.0% from the prior year.

Share Buybacks

$332.0M

5Y CAGR+6.0%

10Y CAGR-2.6%

Clorox Co Del spent $332.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$220.0M

YoY+3.8%

5Y CAGR-2.8%

10Y CAGR+5.8%

Clorox Co Del invested $220.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.8% from the prior year.

CLX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$7.1B+0.2%	$7.1B-4.0%	$7.4B+4.0%	$7.1B-3.2%	$7.3B+9.2%	$6.7B
Cost of Revenue	$3.9B-3.8%	$4.0B-9.7%	$4.5B-1.8%	$4.6B+10.1%	$4.1B+13.2%	$3.7B
Gross Profit	$3.2B+5.4%	$3.0B+4.8%	$2.9B+14.3%	$2.5B-20.4%	$3.2B+4.4%	$3.1B
R&D Expenses	$121.0M-4.0%	$126.0M-8.7%	$138.0M+4.5%	$132.0M-11.4%	$149.0M+2.8%	$145.0M
SG&A Expenses	$1.1B-3.7%	$1.2B-1.4%	$1.2B+24.0%	$954.0M-5.0%	$1.0B+3.6%	$969.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$88.0M-2.2%	$90.0M0.0%	$90.0M-15.1%	$106.0M+7.1%	$99.0M0.0%	$99.0M
Income Tax	$254.0M+139.6%	$106.0M+37.7%	$77.0M-43.4%	$136.0M-24.9%	$181.0M-26.4%	$246.0M
Net Income	$810.0M+189.3%	$280.0M+87.9%	$149.0M-67.7%	$462.0M-34.9%	$710.0M-24.4%	$939.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	$5.58-24.2%	$7.36

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.7B+17.1%	$1.4B-28.1%	$2.0B+19.2%	$1.7B-1.1%	$1.7B-4.3%	$1.8B-7.4%	$1.9B+4.9%	$1.8B
Cost of Revenue	$951.0M+14.2%	$833.0M-21.7%	$1.1B+15.2%	$924.0M-2.5%	$948.0M-0.7%	$955.0M-6.3%	$1.0B-2.8%	$1.0B
Gross Profit	$722.0M+21.1%	$596.0M-35.5%	$924.0M+24.2%	$744.0M+0.8%	$738.0M-8.6%	$807.0M-8.7%	$884.0M+15.4%	$766.0M
R&D Expenses	$29.0M+3.6%	$28.0M-12.5%	$32.0M+18.5%	$27.0M-12.9%	$31.0M0.0%	$31.0M-6.1%	$33.0M+3.1%	$32.0M
SG&A Expenses	$262.0M-5.4%	$277.0M-6.4%	$296.0M+10.9%	$267.0M-4.6%	$280.0M-0.4%	$281.0M+4.9%	$268.0M-11.0%	$301.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$25.0M+8.7%	$23.0M+4.5%	$22.0M-4.3%	$23.0M+4.5%	$22.0M+4.8%	$21.0M0.0%	$21.0M-4.5%	$22.0M
Income Tax	$54.0M+116.0%	$25.0M-66.2%	$74.0M+17.5%	$63.0M+46.5%	$43.0M-41.9%	$74.0M+37.0%	$54.0M+575.0%	$8.0M
Net Income	$157.0M+96.3%	$80.0M-75.9%	$332.0M+78.5%	$186.0M-3.6%	$193.0M+94.9%	$99.0M-54.2%	$216.0M+523.5%	-$51.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.6B-3.3%	$5.8B-3.3%	$5.9B-3.5%	$6.2B-2.8%	$6.3B+1.9%	$6.2B
Current Assets	$1.6B-0.9%	$1.6B-11.3%	$1.8B+6.0%	$1.7B-5.7%	$1.8B-9.5%	$2.0B
Cash & Equivalents	$167.0M-17.3%	$202.0M-45.0%	$367.0M+100.5%	$183.0M-42.6%	$319.0M-63.4%	$871.0M
Inventory	$523.0M-17.9%	$637.0M-8.5%	$696.0M-7.8%	$755.0M+0.4%	$752.0M+65.6%	$454.0M
Accounts Receivable	N/A	N/A	N/A	N/A	$604.0M-6.8%	$648.0M
Goodwill	$1.2B+0.1%	$1.2B-1.9%	$1.3B-19.6%	$1.6B-1.1%	$1.6B-0.1%	$1.6B
Total Liabilities	$5.1B-3.4%	$5.3B-5.4%	$5.6B+2.4%	$5.4B-5.5%	$5.7B+8.2%	$5.3B
Current Liabilities	$1.9B+21.9%	$1.6B-17.9%	$1.9B+7.5%	$1.8B-13.2%	$2.1B+45.0%	$1.4B
Long-Term Debt	$2.5B+0.1%	$2.5B+0.2%	$2.5B+0.1%	$2.5B-0.4%	$2.5B-10.6%	$2.8B
Total Equity	$321.0M-2.1%	$328.0M+49.1%	$220.0M-60.4%	$556.0M+35.3%	$411.0M-54.7%	$908.0M
Retained Earnings	$432.0M+72.8%	$250.0M-57.1%	$583.0M-44.4%	$1.0B+1.2%	$1.0B-71.0%	$3.6B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$5.6B+1.5%	$5.5B-0.6%	$5.6B+0.9%	$5.5B-1.2%	$5.6B+1.5%	$5.5B-4.4%	$5.8B-0.9%	$5.8B
Current Assets	$1.7B+1.9%	$1.7B+5.4%	$1.6B+1.1%	$1.6B-2.6%	$1.6B+3.6%	$1.6B-2.8%	$1.6B-2.3%	$1.7B
Cash & Equivalents	$227.0M+36.7%	$166.0M-0.6%	$167.0M-26.1%	$226.0M-22.1%	$290.0M+4.3%	$278.0M+37.6%	$202.0M-7.8%	$219.0M
Inventory	$608.0M+5.4%	$577.0M+10.3%	$523.0M-17.6%	$635.0M+7.3%	$592.0M-0.3%	$594.0M-6.8%	$637.0M-5.5%	$674.0M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.2B+0.3%	$1.2B-0.2%	$1.2B+0.6%	$1.2B+0.2%	$1.2B-1.1%	$1.2B+0.4%	$1.2B-0.1%	$1.2B
Total Liabilities	$5.6B+3.5%	$5.4B+6.1%	$5.1B-4.6%	$5.3B-2.5%	$5.5B+3.5%	$5.3B+0.3%	$5.3B-5.2%	$5.5B
Current Liabilities	$2.3B+5.1%	$2.2B+16.4%	$1.9B-11.0%	$2.2B+24.6%	$1.7B+9.6%	$1.6B+0.3%	$1.6B-14.7%	$1.8B
Long-Term Debt	$2.5B0.0%	$2.5B0.0%	$2.5B0.0%	$2.5B0.0%	$2.5B0.0%	$2.5B0.0%	$2.5B0.0%	$2.5B
Total Equity	-$125.0M-468.2%	-$22.0M-106.9%	$321.0M+1088.9%	$27.0M+165.9%	-$41.0M-168.3%	$60.0M-81.7%	$328.0M+260.4%	$91.0M
Retained Earnings	$190.0M-5.0%	$200.0M-53.7%	$432.0M+336.4%	$99.0M+45.6%	$68.0M+119.4%	$31.0M-87.6%	$250.0M+635.3%	$34.0M

CLX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$981.0M+41.2%	$695.0M-40.0%	$1.2B+47.3%	$786.0M-38.4%	$1.3B-17.5%	$1.5B
Capital Expenditures	$220.0M+3.8%	$212.0M-7.0%	$228.0M-9.2%	$251.0M-24.2%	$331.0M+30.3%	$254.0M
Free Cash Flow	$761.0M+57.6%	$483.0M-48.1%	$930.0M+73.8%	$535.0M-43.4%	$945.0M-26.9%	$1.3B
Investing Cash Flow	-$94.0M+46.3%	-$175.0M+21.5%	-$223.0M+2.6%	-$229.0M+49.3%	-$452.0M-79.4%	-$252.0M
Financing Cash Flow	-$924.0M-41.1%	-$655.0M+13.0%	-$753.0M-9.3%	-$689.0M+50.5%	-$1.4B-166.0%	-$523.0M
Dividends Paid	$602.0M+1.2%	$595.0M+2.1%	$583.0M+2.1%	$571.0M+2.3%	$558.0M+4.7%	$533.0M
Share Buybacks	$332.0M	$0	$0-100.0%	$25.0M-97.2%	$905.0M+264.9%	$248.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$311.0M+234.4%	$93.0M-68.4%	$294.0M+2.8%	$286.0M+58.9%	$180.0M-18.6%	$221.0M-35.0%	$340.0M+86.8%	$182.0M
Capital Expenditures	$42.0M+16.7%	$36.0M-52.0%	$75.0M+41.5%	$53.0M0.0%	$53.0M+35.9%	$39.0M-51.9%	$81.0M+47.3%	$55.0M
Free Cash Flow	$269.0M+371.9%	$57.0M-74.0%	$219.0M-6.0%	$233.0M+83.5%	$127.0M-30.2%	$182.0M-29.7%	$259.0M+103.9%	$127.0M
Investing Cash Flow	-$43.0M-26.5%	-$34.0M+55.3%	-$76.0M-43.4%	-$53.0M+1.9%	-$54.0M-160.7%	$89.0M+209.9%	-$81.0M-113.2%	-$38.0M
Financing Cash Flow	-$210.0M-255.9%	-$59.0M+78.9%	-$279.0M+6.7%	-$299.0M-174.3%	-$109.0M+54.0%	-$237.0M+13.2%	-$273.0M+1.8%	-$278.0M
Dividends Paid	$151.0M0.0%	$151.0M+0.7%	$150.0M0.0%	$150.0M-0.7%	$151.0M0.0%	$151.0M+1.3%	$149.0M-0.7%	$150.0M
Share Buybacks	$127.0M-1.6%	$129.0M+72.0%	$75.0M	$0-100.0%	$150.0M+40.2%	$107.0M	$0	$0

CLX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	45.2%+2.3pp	43.0%+3.6pp	39.4%+3.6pp	35.8%-7.8pp	43.6%-2.0pp	45.6%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	11.4%+7.5pp	4.0%+1.9pp	2.0%-4.5pp	6.5%-3.2pp	9.7%-4.3pp	14.0%
Return on Equity	252.3%+167.0pp	85.4%+17.6pp	67.7%-15.4pp	83.1%-89.7pp	172.8%+69.3pp	103.4%
Return on Assets	14.6%+9.7pp	4.9%+2.4pp	2.5%-5.0pp	7.5%-3.7pp	11.2%-3.9pp	15.1%
Current Ratio	0.84-0.2	1.03+0.1	0.95-0.0	0.97+0.1	0.89-0.5	1.42
Debt-to-Equity	7.74+0.2	7.56-3.7	11.26+6.8	4.45-1.6	6.04+3.0	3.06
FCF Margin	10.7%+3.9pp	6.8%-5.8pp	12.6%+5.1pp	7.5%-5.3pp	12.9%-6.3pp	19.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	43.2%+1.4pp	41.7%-4.8pp	46.5%+1.9pp	44.6%+0.8pp	43.8%-2.0pp	45.8%-0.7pp	46.5%+4.2pp	42.2%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	9.4%+3.8pp	5.6%-11.1pp	16.7%+5.6pp	11.2%-0.3pp	11.5%+5.8pp	5.6%-5.7pp	11.3%+14.2pp	-2.8%
Return on Equity	N/A	N/A	103.4%-585.5pp	688.9%	N/A	165.0%+99.1pp	65.8%+121.9pp	-56.0%
Return on Assets	2.8%+1.4pp	1.5%-4.5pp	6.0%+2.6pp	3.4%-0.1pp	3.5%+1.7pp	1.8%-2.0pp	3.8%+4.6pp	-0.9%
Current Ratio	0.74-0.0	0.76-0.1	0.84+0.1	0.74-0.2	0.94-0.1	1.00-0.0	1.03+0.1	0.90
Debt-to-Equity	-19.89+93.1	-112.95-120.7	7.74-84.2	91.96+152.5	-60.56-101.9	41.37+33.8	7.56-19.7	27.25
FCF Margin	16.1%+12.1pp	4.0%-7.0pp	11.0%-2.9pp	14.0%+6.4pp	7.5%-2.8pp	10.3%-3.3pp	13.6%+6.6pp	7.0%

Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Church & Dwight Co Inc CHD

$22.0B

Hims & Hers Health Inc HIMS

$4.4B

Kimberly-Clark Corp KMB

$31.9B

Estee Lauder Companies EL

$25.0B

Colgate Palmolive Co CL

$68.3B

Frequently Asked Questions

What is Clorox Co Del's annual revenue?

Clorox Co Del (CLX) reported $7.1B in total revenue for fiscal year 2025. This represents a 0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Clorox Co Del's revenue growing?

Clorox Co Del (CLX) revenue grew by 0.2% year-over-year, from $7.1B to $7.1B in fiscal year 2025.

Is Clorox Co Del profitable?

Yes, Clorox Co Del (CLX) reported a net income of $810.0M in fiscal year 2025, with a net profit margin of 11.4%.

How much debt does Clorox Co Del have?

As of fiscal year 2025, Clorox Co Del (CLX) had $167.0M in cash and equivalents against $2.5B in long-term debt.

What is Clorox Co Del's gross margin?

Clorox Co Del (CLX) had a gross margin of 45.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Clorox Co Del's net profit margin?

Clorox Co Del (CLX) had a net profit margin of 11.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Clorox Co Del's return on equity (ROE)?

Clorox Co Del (CLX) has a return on equity of 252.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Clorox Co Del's free cash flow?

Clorox Co Del (CLX) generated $761.0M in free cash flow during fiscal year 2025. This represents a 57.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Clorox Co Del's operating cash flow?

Clorox Co Del (CLX) generated $981.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Clorox Co Del's total assets?

Clorox Co Del (CLX) had $5.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Clorox Co Del's capital expenditures?

Clorox Co Del (CLX) invested $220.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Clorox Co Del spend on research and development?

Clorox Co Del (CLX) invested $121.0M in research and development during fiscal year 2025.

Does Clorox Co Del buy back shares?

Yes, Clorox Co Del (CLX) spent $332.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Clorox Co Del have outstanding?

Clorox Co Del (CLX) had 122M shares outstanding as of fiscal year 2025.

What is Clorox Co Del's current ratio?

Clorox Co Del (CLX) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Clorox Co Del's debt-to-equity ratio?

Clorox Co Del (CLX) had a debt-to-equity ratio of 7.74 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Clorox Co Del's return on assets (ROA)?

Clorox Co Del (CLX) had a return on assets of 14.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Clorox Co Del's Piotroski F-Score?

Clorox Co Del (CLX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Clorox Co Del's earnings high quality?

Clorox Co Del (CLX) has an earnings quality ratio of 1.21x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Clorox Co Del?

Clorox Co Del (CLX) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.